newsfilter
← Earnings
Earnings Releases·

TRexBio — Third Quarter 2026 Earnings Summary

  • Net loss widened to $13.2 million in Q3 2026 from $7.9 million in the prior year period, driven by R&D expenses rising to $11.4 million and G&A expenses increasing to $2.5 million.
  • The company completed an IPO in October 2026, generating $119.0 million in net proceeds, which extends its cash runway into the second half of 2029.
  • Clinical progress includes positive Phase 1a results for TRB-061 in atopic dermatitis, with Phase 1b data expected mid-2027 and a Phase 1 trial for TRB-071 anticipated in the first half of 2027.
  • Eli Lilly plans to advance the partnered asset TRB-051 into a Phase 2a trial for lupus with cutaneous involvement.
  • A material weakness was identified in internal controls over financial reporting, and the company anticipates substantial losses due to its pre-commercial stage and reliance on third-party clinical development.
Company
TREX BIO INC
Sector
Healthcare
Industry
Biotechnology